【摘要】 目的：评估卡瑞利珠单抗在食管癌患者中的疗效与发生反应性皮肤毛细血管增生症（RCCEP）之间的关系。方法：选取2020年11月1日～2022年4月30日在本院使用卡瑞利珠单抗治疗的食管癌患者96例作为研究对象，记录患者发生RCCEP的情况，采用Kaplan-Meier法分析生存曲线，通过对数秩检验进行单变量分析。结果：在95例使用卡瑞利珠单抗治疗的食管癌患者中，RCCEP的发生率为64.2%(61/95);RCCEP为1级者55例（57.9%）、2级5例（5.3%）、3级1例（1.1%）。发生RCCEP的患者中位无进展生存期（PFS）为23.1个月，未发生RCCEP的患者中位PFS为18.8个月。发生RCCEP患者的中位总生存期（OS）为35.7个月，未发生RCCEP的患者中位OS为18.7个月。结论：本研究中食管癌患者的RCCEP发病率与PFS和OS之间存在正相关性（P<0.05）。发生RCCEP的食管癌患者（ECOG≤1）的OS和PFS更长。更多还原

【Abstract】 Objective: To evaluate the relationship between the efficacy of camrelizumab and the occurrence of reactive cutaneous capillary endothelial proliferation(RCCEP) in patients with esophageal carcinoma.Methods: Ninety-six(96) patients with esophageal carcinoma treated with camrelizumab between 1November 2020 and 30 April 2022 in our hospital were selected as the study population, for whom the occurrences of RCCEP were recorded. The Kaplan-Meier method was used to analyze the survival curves, and univariate analysis was performed using log-rank test. Results: RCCEP occurred in 64.2%(61/95) of the 95patients with esophageal carcinoma treated by camrelizumab, including Grade 1 in 55 patients(57.9%), Grade 2 in 5 patients(5.3%) and Grade 3 in 1 patient(1.1%), respectively. The median progression-free survival(PFS)was 23.1 months for patients with RCCEP and 18.8 months for patients without RCCEP, respectively. The median overall survival(OS) was 35.7 months for patients with RCCEP and 18.7 months for patients without RCCEP, respectively. Conclusion: The present study reveals a positive correlation of the RCCEP incidence with PFS and OS in the patients with esophageal carcinoma(P<0.05). OS and PFS were longer in patients with esophageal carcinoma(ECOG≤1) who experienced RCCEP.更多还原